Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma
Open Access
- 4 August 2020
- journal article
- research article
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 54 (5) , 413-419
Abstract
Tumour associated trypsin inhibitor (TATI) is a peptide that is a marker for several tumours. TATI may also behave as an acute phase reactant in severe inflammatory disease. Overexpression of TATI ...Keywords
This publication has 27 references indexed in Scilit:
- Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)British Journal of Cancer, 2013
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI: Journal of the National Cancer Institute, 2005
- Original and reviewed nuclear grading according to the Fuhrman systemCancer, 2004
- Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian CancerClinical Cancer Research, 2004
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- Serum Levels of Tumor Associated Trypsin Inhibitor (TATT) and Glomerular Filtration RateRenal Failure, 1998
- Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin systemJournal of Immunological Methods, 1993
- Pancreatic secretory trypsin inhibitor as an acute phase reactantClinical Biochemistry, 1988
- Elevated Pancreatic Secretory Trypsin Inhibitor Levels during Severe Inflammatory Disease, Renal Insufficiency, and after Various Surgical ProceduresScandinavian Journal of Gastroenterology, 1986